SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma expects generics to drive growth in coming years

25 Sep 2017 Evaluate

Glenmark Pharmaceuticals is expecting to achieve a significant growth in next three to four years on the back of strong pipeline of speciality and innovative products. Speciality and innovative products will comprise 30 per cent of its revenues by 2025.

The next few years will see consistent revenues and profitability without the need for inorganic growth through acquisitions. Over the last few years the company has invested significantly to mark the step-wise transition from generics to an innovation-driven organisation.

Glenmark Pharma. Share Price

2265.25 41.40 (1.86%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: